Overall survival of patients with mCRC carrying a tumor with a KRAS G12, G13, Q61, K117, or A146 mutation. Median survival in months was 26.4 (KRAS G12), undefined (KRAS G13), 27.9 (KRAS Q61), 20.6 (KRAS K117), and 10.7 (KRAS A146). aA significant difference was observed between KRAS G12 and A146 (log-rank P = .0045), by the Mantel-Cox log-rank test using a Bonferroni-corrected threshold for every combination of P < .005 for significance. mCRC, metastatic colorectal cancer.